The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer

The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer

The availability of bromodomain and extra-terminal inhibitors (BETi) has enabled translational epigenetic studies in cancer. BET proteins regulate transcription by selectively recognizing acetylated lysine residues on chromatin. BETi compete with this process leading to both downregulation and upreg...

Full description

Bibliographic Details
Main Authors: da Motta, L L, Ledaki, I, Purshouse, K, Haider, S, De Bastiani, M A, Baban, D, Morotti, M, Steers, G, Wigfield, S, Bridges, E, Li, J-L, Knapp, S, Ebner, D, Klamt, F, Harris, A L, McIntyre, A
Format: Online
Language:English
Published: Nature Publishing Group 2017
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061082/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061082/

Similar Items